Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study

Abstract Background With life span extending, breast cancer (BC) survivors may face the possibility of developing second primary cancer (SPC) and considerably shorten survivorship. However, little is known about multiple primary cancer (MPC) patients with nonmetastatic breast cancer as a first prima...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shengnan Bao, Mengping Jiang, Xi Wang, Yijia Hua, Tianyu Zeng, Yiqi Yang, Fan Yang, Xueqi Yan, Chunxiao Sun, Mengzhu Yang, Ziyi Fu, Xiang Huang, Jun Li, Hao Wu, Wei Li, Jinhai Tang, Yongmei Yin
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2021
Materias:	breast cancer breast cancer‐specific survival multiple primary cancer nomogram second primary cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/a0dcf298c0364db1a979aba0ed63fa50
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a0dcf298c0364db1a979aba0ed63fa50
record_format	dspace
spelling	oai:doaj.org-article:a0dcf298c0364db1a979aba0ed63fa502021-12-01T04:49:16ZNonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study2045-763410.1002/cam4.4351https://doaj.org/article/a0dcf298c0364db1a979aba0ed63fa502021-12-01T00:00:00Zhttps://doi.org/10.1002/cam4.4351https://doaj.org/toc/2045-7634Abstract Background With life span extending, breast cancer (BC) survivors may face the possibility of developing second primary cancer (SPC) and considerably shorten survivorship. However, little is known about multiple primary cancer (MPC) patients with nonmetastatic breast cancer as a first primary malignancy (BCFPM). Methods Here, we retrospectively analyzed data on cancer survivors with BCFPM diagnosed between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The prognostic factors for breast cancer‐specific survival (BCSS) were ascertained by the stepwise regression analysis and a competing risk model, and were integrated to the establishment of prognostic nomogram, of which the accuracy was measured by the calibration curve and the concordance index (C‐index). Results In total, 8616 patients were identified with 4.6% of 3‐year breast cancer‐ specific death (BCSD) and 8.6% of 5‐year BCSD. The most common SPC among BCFPM patients were female BC and lung cancer. Besides, the median latency time between BC and SPC was 22 months. At a ratio of 7:3, all patients were randomly categorized into a training cohort (n = 6032) and a validation cohort (n = 2584). By a proportional subdistribution hazards regression analysis, the following factors were considered to own independent prognostic abilities of BCSS: subtypes, grade, T classification, N classification, radiation, and sites of SPC. The nomogram could accurately predict 3‐year and 5‐year breast cancer‐associated survival of BCFPM patients with high internal and external validated C‐index, 0.715 (95% CI, 0.691–0.739), and 0.683 (95% CI, 0.642–0.724), respectively. Conclusions BC survivors remained a high risk of developing SPC and considerably shortened survival time. In this study, a favorable nomogram was constructed to as a prediction model for 3‐year and 5‐year BCSS of BCFPM patients, largely intending to prolong the life of these patients by assisting clinicians to make individualized follow‐up plans.Shengnan BaoMengping JiangXi WangYijia HuaTianyu ZengYiqi YangFan YangXueqi YanChunxiao SunMengzhu YangZiyi FuXiang HuangJun LiHao WuWei LiJinhai TangYongmei YinWileyarticlebreast cancerbreast cancer‐specific survivalmultiple primary cancernomogramsecond primary cancerNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancer Medicine, Vol 10, Iss 23, Pp 8662-8672 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	breast cancer breast cancer‐specific survival multiple primary cancer nomogram second primary cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	breast cancer breast cancer‐specific survival multiple primary cancer nomogram second primary cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Shengnan Bao Mengping Jiang Xi Wang Yijia Hua Tianyu Zeng Yiqi Yang Fan Yang Xueqi Yan Chunxiao Sun Mengzhu Yang Ziyi Fu Xiang Huang Jun Li Hao Wu Wei Li Jinhai Tang Yongmei Yin Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
description	Abstract Background With life span extending, breast cancer (BC) survivors may face the possibility of developing second primary cancer (SPC) and considerably shorten survivorship. However, little is known about multiple primary cancer (MPC) patients with nonmetastatic breast cancer as a first primary malignancy (BCFPM). Methods Here, we retrospectively analyzed data on cancer survivors with BCFPM diagnosed between 2010 and 2015 from the Surveillance, Epidemiology, and End Results (SEER) database. The prognostic factors for breast cancer‐specific survival (BCSS) were ascertained by the stepwise regression analysis and a competing risk model, and were integrated to the establishment of prognostic nomogram, of which the accuracy was measured by the calibration curve and the concordance index (C‐index). Results In total, 8616 patients were identified with 4.6% of 3‐year breast cancer‐ specific death (BCSD) and 8.6% of 5‐year BCSD. The most common SPC among BCFPM patients were female BC and lung cancer. Besides, the median latency time between BC and SPC was 22 months. At a ratio of 7:3, all patients were randomly categorized into a training cohort (n = 6032) and a validation cohort (n = 2584). By a proportional subdistribution hazards regression analysis, the following factors were considered to own independent prognostic abilities of BCSS: subtypes, grade, T classification, N classification, radiation, and sites of SPC. The nomogram could accurately predict 3‐year and 5‐year breast cancer‐associated survival of BCFPM patients with high internal and external validated C‐index, 0.715 (95% CI, 0.691–0.739), and 0.683 (95% CI, 0.642–0.724), respectively. Conclusions BC survivors remained a high risk of developing SPC and considerably shortened survival time. In this study, a favorable nomogram was constructed to as a prediction model for 3‐year and 5‐year BCSS of BCFPM patients, largely intending to prolong the life of these patients by assisting clinicians to make individualized follow‐up plans.
format	article
author	Shengnan Bao Mengping Jiang Xi Wang Yijia Hua Tianyu Zeng Yiqi Yang Fan Yang Xueqi Yan Chunxiao Sun Mengzhu Yang Ziyi Fu Xiang Huang Jun Li Hao Wu Wei Li Jinhai Tang Yongmei Yin
author_facet	Shengnan Bao Mengping Jiang Xi Wang Yijia Hua Tianyu Zeng Yiqi Yang Fan Yang Xueqi Yan Chunxiao Sun Mengzhu Yang Ziyi Fu Xiang Huang Jun Li Hao Wu Wei Li Jinhai Tang Yongmei Yin
author_sort	Shengnan Bao
title	Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
title_short	Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
title_full	Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
title_fullStr	Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
title_full_unstemmed	Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study
title_sort	nonmetastatic breast cancer patients subsequently developing second primary malignancy: a population‐based study
publisher	Wiley
publishDate	2021
url	https://doaj.org/article/a0dcf298c0364db1a979aba0ed63fa50
work_keys_str_mv	AT shengnanbao nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT mengpingjiang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT xiwang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT yijiahua nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT tianyuzeng nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT yiqiyang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT fanyang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT xueqiyan nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT chunxiaosun nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT mengzhuyang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT ziyifu nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT xianghuang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT junli nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT haowu nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT weili nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT jinhaitang nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy AT yongmeiyin nonmetastaticbreastcancerpatientssubsequentlydevelopingsecondprimarymalignancyapopulationbasedstudy
_version_	1718405740410961920

Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population‐based study

Ejemplares similares